WORLD'S FIRST THERAPY TO REVERSE SPINAL CORD INJURY ENTERS HUMAN TRIAL

Summary from the TLDR newsletter

The world's first regenerative cell therapy for treating spinal injuries has been granted approval for a registrational Phase I clinical trial. Chinese biotechnology company XellSmart's allogeneic induced pluripotent stem cells regenerative therapy aims to repair injuries and provide the foundation to regrow all the cells needed to return function to the damaged region. It doesn't require harvesting cells from a patient and is a 'one size fits all' treatment that will work with anyone who has a spinal cord injury. If it passes through the trial phases, the treatment will be easy to manufacture and scale for broad access.